Vfend (voriconazole)
- Region
- 🇪🇺 EU
- Active substance
- voriconazole
- Company
- Pfizer Europe MA EEIG
- Status
- Authorised
- Therapeutic area
- Candidiasis; Mycoses; Aspergillosis
- CHMP opinion
- Thu 13 Dec 2001
- EU approval
- Tue 19 Mar 2002
- Application
- EMEA/H/C/000387
- ATC
- J02AC03
- Official record
- www.ema.europa.eu
Indication
Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: treatment of invasive aspergillosis; treatment of in candidaemianon-neutropenic patients; treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei); Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp. Vfend should be administered primarily to patients with progressive, possibly life-threatening infections. Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Voriconazole Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Voriconazole Hikma (previously Voriconazole Hospira) Authorised · Hikma Farmaceutica (Portugal) S.A.
Follow Vfend
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.